Biotech

Arch Biopartners provided shareholders with an update on the good manufacturing practice production campaign for AB569.

Arch Biopartners (TSXV:ARCH; OTCBB:ACHFF) provided shareholders with an update on the good manufacturing practice production campaign for AB569.
As quoted in the press release:

AB569 is a potential stand alone or complementary treatment to existing and emerging standard of care for COPD and CF patients that have reduced lung function due to Pseudomonas aeruginosa (P. aeruginosa) and other multi-drug resistant bacterial infections in the lung.
P. aeruginosa affects the majority of adult CF patients and often infects patients from childhood onward. Arch has received orphan drug designation in the U.S. for AB569 in the treatment of CF patients with P. aeruginosa lung infections, Arch has also received orphan medicinal product designation in Europe for AB569 for the treatment of CF.
Manufacturing of AB569 on schedule
AB569 is mainly composed of two compounds: Ethylenediaminetetraacetic acid (EDTA) and Sodium Nitrite (NaNO2), which are already approved by the U.S. Food and Drug Administration (FDA) for use in humans in other medical applications.

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20617.88+234.13
TSXV714.72+12.98
DOW32731.54+611.26
S&P 5004070.66+91.93
NASD11787.00+352.26
ASX7155.20+26.40

COMMODITIES

Commodities
Gold1849.23-4.82
Silver21.97-0.01
Copper4.27+0.01
Palladium2012.00+14.00
Platinum950.00+3.00
Oil114.31+3.98
Heating Oil3.84+0.10
Natural Gas9.30+0.33

DOWNLOAD FREE REPORTS

×